Invokana Archives -

Johnson & Johnson’s SGLT2 inhibitor Invokana has been shown to have a significant effect on heart failure symptoms

Smartphone-powered trial backs J&J’s Invokana for heart failure

https://pharmaphorum.com/news/smartphone-powered-trial-backs-jjs-invokana-for-heart-failure/

Bayer’s blockbuster ambitions for diabetic kidney disease (DKD) drug candidate finerenone look a lot firmer with the publication

Bayer data for kidney disease hope finerenone sets up filings

https://pharmaphorum.com/news/bayer-data-for-kidney-disease-hope-finerenone-sets-up-filings/

Janssen’s Invokana is playing catch-up in the emerging heart failure market for SGLT2 inhibitors, but hopes a real-world

Janssen taps wearable tech in Invokana heart failure trial

https://pharmaphorum.com/news/janssen-taps-wearable-tech-in-invokana-heart-failure-trial/

Johnson & Johnson finally has some good news to report for its diabetes blockbuster Invokana, after the FDA

FDA clears cardiovascular claim for J&J’s Invokana

https://pharmaphorum.com/news/fda-clears-cardiovascular-claim-for-jjs-invokana/

Invokana